Precigen is a biotechnology business based in the US. Precigen shares (PGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.91 – an increase of 8.68% over the previous week. Precigen employs 202 staff and has a trailing 12-month revenue of around $4.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.91 |
|---|---|
| 52-week range | $0.82 - $1.93 |
| 50-day moving average | $1.02 |
| 200-day moving average | $1.35 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.54 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8692 from 2024-10-15
| 1 week (2024-10-11) | -3.27% |
|---|---|
| 1 month (2024-09-18) | -16.42% |
| 3 months (2024-07-18) | -47.64% |
| 6 months (2024-04-18) | -34.15% |
| 1 year (2023-10-18) | -25.07% |
|---|---|
| 2 years (2022-10-18) | -53.27% |
| 3 years (2021-10-18) | 4.72 |
| 5 years (2019-10-18) | 5.05 |
| Revenue TTM | $4.4 million |
|---|---|
| Gross profit TTM | $20.6 million |
| Return on assets TTM | -42.32% |
| Return on equity TTM | -129.32% |
| Profit margin | 0% |
| Book value | $0.17 |
| Market Capitalization | $254.4 million |
TTM: trailing 12 months
We're not expecting Precigen to pay a dividend over the next 12 months.
Over the last 12 months, Precigen's shares have ranged in value from as little as $0.8239 up to $1.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Precigen's is 1.657. This would suggest that Precigen's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.